NIH Research Funding Reality Fails To Keep Pace With Rhetoric

SCIENCE PRIORITY: Sen. Phil Gramm (R-Texas) is sponsoring legislation to double all nondefense research funding in 10 years. Congress has been discussing proposals to double biomedical research funding over five years, double nondefense research funding over 10 years, and raise additional funds to benefit science. So should scientists start celebrating a renaissance in research funding? INFLATION EROSION: AAAS's Al Teich notes that science funding in many categories has declined over the pas

Written byPaul Smaglik
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share


SCIENCE PRIORITY: Sen. Phil Gramm (R-Texas) is sponsoring legislation to double all nondefense research funding in 10 years.
Congress has been discussing proposals to double biomedical research funding over five years, double nondefense research funding over 10 years, and raise additional funds to benefit science. So should scientists start celebrating a renaissance in research funding?


INFLATION EROSION: AAAS's Al Teich notes that science funding in many categories has declined over the past five years after inflation.
Not quite, says Al Teich, director of science and policy programs at the American Association for the Advancement of Science (AAAS). "You can't spend resolutions."

On October 22, Sens. Phil Gramm (R-Texas), known as a fiscal conservative and deficit hawk, and Joseph Lieberman (D-Conn.) introduced a bill asking Congress to double all federal nondefense research funding over 10 years. Last summer, both the Senate and the House of Representatives voted in favor of resolutions ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies